GC
LXRX icon

Guggenheim Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

Guggenheim Capital’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-4,420
Closed -$29K – 3073
2015
Q1 		$29K Buy
4,420
+399
+10% +$2.73K ﹤0.01% 2974
2014
Q4 		$26K Buy
4,021
+1,553
+63% +$12.5K ﹤0.01% 2956
2014
Q3 		$24K Sell
2,468
-252
-9% -$2.69K ﹤0.01% 2962
2014
Q2 		$31K Sell
2,720
-223
-8% -$2.4K ﹤0.01% 3130
2014
Q1 		$36K Sell
2,943
-468
-14% -$5.98K ﹤0.01% 3173
2013
Q4 		$43K Buy
3,411
+304
+10% +$4.84K ﹤0.01% 3073
2013
Q3 		$52K Buy
3,107
+315
+11% +$5.28K ﹤0.01% 2933
2013
Q2 		$42K Buy
+2,792
New +$42.4K ﹤0.01% 2924

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $14.7B AUM 42.39% 1-Year Est. Return

Guggenheim Capital's LXRX Position: Q2 2015 in Review

Guggenheim Capital sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2015, closing a stake of 4,420 shares — an estimated $29K sold.

Guggenheim Capital first reported a position in LXRX in Q2 2013 and held it in 8 quarters. The position peaked at $52K in Q3 2013. 94 funds tracked by Wall St. Rank hold LXRX as of Q2 2015.

  • Guggenheim Capital reported no remaining Lexicon Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Guggenheim Capital sold 4,420 Lexicon Pharmaceuticals shares in Q2 2015, an estimated $29K.
  • Guggenheim Capital first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 8 quarters.
  • Guggenheim Capital's Lexicon Pharmaceuticals position peaked at $52K in Q3 2013.
  • 94 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2015.

Based on Guggenheim Capital's 13F filing for Q2 2015, filed 14 Aug 2015.